特发性腹膜后纤维化:长期复发风险及预测因素
本研究为回顾性队列研究,纳入50例特发性腹膜后纤维化(IRF)患者,前瞻性随访中位8.9年。全部患者获得临床缓解,但19例(38%)出现至少一次复发,5年、10年、15年累积复发率分别为21%、41%、48%。男性及基线抗核抗体阳性与复发风险升高相关,而单用糖皮质激素或联合他莫昔芬与较低复发率相关。
要点
- IRF患者长期复发常见,15年累积复发率可达48%。
- 男性及基线抗核抗体阳性是复发的独立预测因素。
- 单用糖皮质激素或联合他莫昔芬可能降低复发风险。
核心结论
- IRF复发常见,男性患者复发更频繁。
- 单用糖皮质激素或联合他莫昔芬与较低复发率相关。
- 抗核抗体阳性与复发的强关联支持IRF的自身免疫发病假说。
研究设计与样本
- 回顾性队列研究,纳入50例IRF患者,在三级转诊中心前瞻性随访8.9年(IQR 4.7-12.7)。
主要发现
- 49例接受药物治疗,35例接受介入操作;全部患者达到临床缓解,其中44例在1年内缓解,其余6例在中位2.95年后缓解。
- 19例(38%)出现至少1次复发,复发中位时间为开始治疗后5.19年。
- 5年、10年、15年累积复发率分别为21%、41%、48%。
- 基线抗核抗体阳性(sHR 5.35,95%CI 2.15-13.27)和男性(sHR 4.94,95%CI 1.32-18.57)与复发相关。
- 1年时较高糖皮质激素剂量(每增加1 mg/d,sHR 0.91,95%CI 0.84-0.98)及单用泼尼松或联合他莫昔芬(sHR 0.25,95%CI 0.07-0.85)与较低复发率相关。
关键数值与推荐
- 临床缓解定义为疾病相关症状和肾积水消退,且CT上腹膜后肿块最大横径减少>50%。
- 复发定义为血清肌酐升高至少30%,或肾积水复发/新发且CT上腹膜后肿块最大横径增加≥20%。
临床怎么用
- 对IRF患者应长期监测复发,尤其男性及抗核抗体阳性者。
- 治疗上可考虑单用糖皮质激素或联合他莫昔芬以降低复发风险。
局限性
- 样本量小且治疗方案存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Idiopathic retroperitoneal fibrosis (IRF) is a rare disorder of unknown cause. Medical therapy can induce remission, but disease relapses are common. This study sought to characterize long-term outcomes of IRF and the factors associated with disease recurrences. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Retrospective analysis of 50 patients with IRF prospectively followed up for 8.9 (IQR, 4.7-12.7) years at a tertiary-care referral center. EXPOSURES: Demographic, clinical, treatment, and laboratory parameters, including measures of autoimmunity. OUTCOME: Disease relapse. ANALYTICAL APPROACH: Proportional hazards analysis for the subdistribution of competing risks. RESULTS: 49 patients received medical treatment and 35 underwent interventional procedures. All patients experienced a clinical response (defined as regression of disease-related symptoms and hydronephrosis, and decrease in the maximal transverse diameter of the retroperitoneal mass on computed tomography of >50%), 44 of whom responded within 1 year. The remaining 6 responded over a median of 2.95 years after starting therapy. 40 patients were alive at last observation, 1 receiving maintenance dialysis and 15 with estimated glomerular filtration rate < 60mL/min/1.73m2. Patient survival at 5, 10, and 15 years was 95%, 84%, and 68%, respectively. 19 (38%) patients had at least 1 relapse (occurring a median of 5.19 years after starting therapy), defined as an increase in serum creatinine level of at least 30% or recurrence/development of hydronephrosis and ≥20% increase in the maximal transverse diameter of the retroperitoneal mass on computed tomography. Cumulative incidences of relapse at 5, 10, and 15 years were 21%, 41%, and 48%, respectively. Baseline antinuclear antibody positivity and male sex were associated with relapse (subdistribution hazard ratios [sHRs] of 5.35 [95% CI, 2.15-13.27] and 4.94 [95% CI, 1.32-18.57], respectively), while higher corticosteroid therapy dosage at 1 year (sHR for relapse per 1-mg/d greater dosage, 0.91 [95% CI, 0.84-0.98]) and treatment with prednisone alone or with tamoxifen (sHR for relapse of 0.25 [95% CI, 0.07-0.85] vs other therapies) were associated with lower rate of relapse. LIMITATIONS: Small sample size and variable approaches to therapy. CONCLUSIONS: IRF relapses were common and were experienced more frequently by male patients. Corticosteroids alone or with tamoxifen were associated with a lower rate of relapse. The strong association of antinuclear antibody positivity with relapse supports the hypothesis of an autoimmune pathogenesis of IRF.
引用
- Raffiotta F, da Silva Escoli R, Quaglini S, et al. Idiopathic Retroperitoneal Fibrosis: Long-term Risk and Predictors of Relapse. Am J Kidney Dis. 2019. PMID: 31204195. doi:10.1053/j.ajkd.2019.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。